Advertisement
Canada markets close in 5 hours 18 minutes
  • S&P/TSX

    21,927.73
    +42.35 (+0.19%)
     
  • S&P 500

    5,099.63
    +51.21 (+1.01%)
     
  • DOW

    38,225.70
    +139.90 (+0.37%)
     
  • CAD/USD

    0.7314
    -0.0009 (-0.12%)
     
  • CRUDE OIL

    83.58
    +0.01 (+0.01%)
     
  • Bitcoin CAD

    87,468.59
    +658.36 (+0.76%)
     
  • CMC Crypto 200

    1,341.68
    -54.85 (-3.92%)
     
  • GOLD FUTURES

    2,348.70
    +6.20 (+0.26%)
     
  • RUSSELL 2000

    1,999.73
    +18.62 (+0.94%)
     
  • 10-Yr Bond

    4.6510
    -0.0550 (-1.17%)
     
  • NASDAQ

    15,910.32
    +298.56 (+1.91%)
     
  • VOLATILITY

    15.23
    -0.14 (-0.91%)
     
  • FTSE

    8,139.68
    +60.82 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6841
    +0.0020 (+0.29%)
     

Were Compass Pathways' Clinical Trial Results Really That Bad?

Compass Pathways (NASDAQ: CMPS) has released data for a phase 2b study of its COMP360 psilocybin treatment for depression. In this Motley Fool Live video recorded on November 15, Motley Fool contributors Keith Speights and Brian Orelli point out that the therapy helped reduce patients' depression symptoms, but the drug's effectiveness seemed to wane over time and adverse effects were seen in patients taking higher doses.